118 related articles for article (PubMed ID: 11485324)
1. Assessment of substrate specificity of hepatitis G virus NS3 protease by a genetic method.
Lee YJ; Kang H; Rho SH; Eom SH; Park WJ
Biochem Biophys Res Commun; 2001 Aug; 286(1):171-5. PubMed ID: 11485324
[TBL] [Abstract][Full Text] [Related]
2. In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis.
Kim SY; Park KW; Lee YJ; Back SH; Goo JH; Park OK; Jang SK; Park WJ
Anal Biochem; 2000 Aug; 284(1):42-8. PubMed ID: 10933854
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the catalytic domain of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase at a resolution of 1.8 A.
Yamashita T; Unno H; Mori Y; Tani H; Moriishi K; Takamizawa A; Agoh M; Tsukihara T; Matsuura Y
Virology; 2008 Apr; 373(2):426-36. PubMed ID: 18201743
[TBL] [Abstract][Full Text] [Related]
4. Internal processing of hepatitis C virus NS3 protein.
Shoji I; Suzuki T; Sato M; Aizaki H; Chiba T; Matsuura Y; Miyamura T
Virology; 1999 Feb; 254(2):315-23. PubMed ID: 9986797
[TBL] [Abstract][Full Text] [Related]
5. Japanese encephalitis virus NS2B-NS3 protease binding to phage-displayed human brain proteins with the domain of trypsin inhibitor and basic region leucine zipper.
Lin CW; Lin KH; Lyu PC; Chen WJ
Virus Res; 2006 Mar; 116(1-2):106-13. PubMed ID: 16289409
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the West Nile virus protease substrate specificity and inhibitors.
Mueller NH; Yon C; Ganesh VK; Padmanabhan R
Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926
[TBL] [Abstract][Full Text] [Related]
7. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity.
Beyer BM; Zhang R; Hong Z; Madison V; Malcolm BA
Proteins; 2001 May; 43(2):82-8. PubMed ID: 11276078
[TBL] [Abstract][Full Text] [Related]
8. Product inhibition of the hepatitis C virus NS3 protease.
Steinkühler C; Biasiol G; Brunetti M; Urbani A; Koch U; Cortese R; Pessi A; De Francesco R
Biochemistry; 1998 Jun; 37(25):8899-905. PubMed ID: 9636031
[TBL] [Abstract][Full Text] [Related]
9. Specific RNA aptamers to NS3 protease domain of hepatitis C virus.
Fukuda K; Vishinuvardhan D; Sekiya S; Kakiuchi N; Shimotohno K; Kumar PK; Nishikawa S
Nucleic Acids Symp Ser; 1997; (37):237-8. PubMed ID: 9586087
[TBL] [Abstract][Full Text] [Related]
10. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain.
Arias CF; Preugschat F; Strauss JH
Virology; 1993 Apr; 193(2):888-99. PubMed ID: 8460492
[TBL] [Abstract][Full Text] [Related]
11. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
12. Redesigning the substrate specificity of the hepatitis C virus NS3 protease.
Failla CM; Pizzi E; De Francesco R; Tramontano A
Fold Des; 1996; 1(1):35-42. PubMed ID: 9079362
[TBL] [Abstract][Full Text] [Related]
13. Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).
Borowski P; Heising MV; Miranda IB; Liao CL; Choe J; Baier A
Biochem Pharmacol; 2008 Jul; 76(1):28-38. PubMed ID: 18479669
[TBL] [Abstract][Full Text] [Related]
14. Determination of the substrate specificity of turnip mosaic virus NIa protease using a genetic method.
Kang H; Lee YJ; Goo JH; Park WJ
J Gen Virol; 2001 Dec; 82(Pt 12):3115-3117. PubMed ID: 11714990
[TBL] [Abstract][Full Text] [Related]
15. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
Chanprapaph S; Saparpakorn P; Sangma C; Niyomrattanakit P; Hannongbua S; Angsuthanasombat C; Katzenmeier G
Biochem Biophys Res Commun; 2005 May; 330(4):1237-46. PubMed ID: 15823576
[TBL] [Abstract][Full Text] [Related]
16. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
[TBL] [Abstract][Full Text] [Related]
17. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.
Ingallinella P; Altamura S; Bianchi E; Taliani M; Ingenito R; Cortese R; De Francesco R; Steinkühler C; Pessi A
Biochemistry; 1998 Jun; 37(25):8906-14. PubMed ID: 9636032
[TBL] [Abstract][Full Text] [Related]
18. Homology modeling and molecular dynamics study of West Nile virus NS3 protease: a molecular basis for the catalytic activity increased by the NS2B cofactor.
Zhou H; Singh NJ; Kim KS
Proteins; 2006 Nov; 65(3):692-701. PubMed ID: 16972281
[TBL] [Abstract][Full Text] [Related]
19. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.
Eckart MR; Selby M; Masiarz F; Lee C; Berger K; Crawford K; Kuo C; Kuo G; Houghton M; Choo QL
Biochem Biophys Res Commun; 1993 Apr; 192(2):399-406. PubMed ID: 8387277
[TBL] [Abstract][Full Text] [Related]
20. Critical point mutations for hepatitis C virus NS3 proteinase.
Yamada K; Mori A; Seki M; Kimura J; Yuasa S; Matsuura Y; Miyamura T
Virology; 1998 Jun; 246(1):104-12. PubMed ID: 9656998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
